Advancing Vision
Research Knowledge
ClearSight monitors the latest developments in inherited retinal disease research — from gene therapy breakthroughs to clinical trial updates — and delivers accurate, accessible information to patients, families, and researchers.
What We Cover
Our AI research engine continuously monitors scientific literature, clinical trial registries, and medical news to keep you informed across four key areas.
Research Publications
Peer-reviewed studies, gene therapy breakthroughs, and preclinical findings translated into accessible summaries.
Clinical Trials
Active and upcoming trials for IRDs — eligibility, phase, endpoints, and enrollment information.
Treatments & Therapies
FDA approvals, compassionate use programs, gene replacement, and emerging therapeutic approaches.
Community News
Conference highlights, patient advocacy updates, funding announcements, and IRD community news.
Disease Library
Comprehensive profiles for 35+ inherited retinal diseases and vision loss conditions across 7 categories.
Latest Research Updates
AI-curated articles on the most recent developments in IRD research.
A New Hope for Bestrophinopathies: Opus Genetics Launches OPGx-BEST1 Clinical Trial
Opus Genetics is initiating a Phase 1 clinical trial (NCT07185256) for OPGx-BEST1, a novel gene therapy aimed at treating Best Vitelliform Macular Dystrophy (BVMD) and Autosomal-Recessive Bestrophinopathy (ARB). This trial will evaluate the safety, tolerability, and preliminary efficacy of a subretinal injection of OPGx-BEST1 over five years, offering a potential new treatment pathway for these inherited retinal diseases.
Unlocking the Secrets of Retinal Diseases: A New Study Seeks Cell Samples to Advance Research
The National Eye Institute (NEI) is recruiting participants for a vital study, NCT01432847, aimed at collecting cell samples from individuals with retinal diseases like Best disease, Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD), as well as healthy volunteers. This research is crucial for understanding these conditions at a cellular level, paving the way for future diagnostic tools and treatments.
Unlocking Insights: A Decade-Long Study to Understand Congenital Muscle Diseases
ClearSight is excited to share details about a crucial, ongoing study, NCT01403402, focused on gathering vital patient and family-reported medical information for a wide range of congenital muscle diseases. This long-term research aims to improve understanding of these complex conditions and ultimately enhance patient care.
Stay Informed on IRD Research
Our advanced engine monitors PubMed, ClinicalTrials.gov, FDA announcements, and leading ophthalmology journals to deliver timely, accurate updates on inherited retinal diseases.